Emcure to Fully Acquire Zuventus Healthcare in ₹724.9 Crore Deal

Glimpse:

In a strategic move to reinforce its domestic presence, Emcure Pharmaceuticals will acquire the remaining 20.42% stake in its subsidiary Zuventus Healthcare for ₹724.9 crore, making it a wholly owned subsidiary. The deal, approved by Emcure’s board, is expected to close in Q2 of FY 2025-26.

Emcure currently holds a 79.58% stake in Zuventus, which has built a strong presence in India’s pharma sector since its founding in 2002. The acquisition supports Emcure’s focus on the Indian market, aiming to unlock operational synergies, fully consolidate financials, and drive long-term value creation as part of its domestic growth strategy.

In a strategic push to consolidate its domestic operations, Emcure Pharmaceuticals has announced its plan to acquire the remaining 20.42% stake in its subsidiary Zuventus Healthcare for a total consideration of ₹724.9 crore. The transaction, approved by Emcure’s board of directors, will be executed in cash, in one or more tranches, and is expected to close in the September quarter of FY 2025–26.

Emcure currently holds a 79.58% stake in Zuventus, a company it initially partnered with in the early 2000s. Founded in 2002, Zuventus has grown into a well-regarded name in the Indian pharmaceutical sector, offering a diverse portfolio across several therapeutic categories.

By making Zuventus a wholly owned subsidiary, Emcure aims to strengthen its hold in the domestic market, which it identifies as a core strategic focus. The company emphasized that the acquisition would enable full financial consolidation, enhance operational synergies, and create long-term value through tighter integration of its product, marketing, and supply chain strategies.

“The domestic market remains a strategic priority for Emcure. This transaction will enable full consolidation of Zuventus and drive long-term value creation,” the company noted in its official filing.

The move is aligned with Emcure’s broader ambition to reinforce its leadership in India’s pharmaceutical space and optimize its integrated operations, especially as competition in the domestic market continues to intensify.